Press Release: Axmed Secures $6M Grant Funding to Scale the Global Infrastructure for Access to Healthcare Products

Dow Jones
02/17

BASEL, Switzerland and NAIROBI, Kenya, Feb. 17, 2026 /PRNewswire/ -- Axmed, a health technology company headquartered in Switzerland with regional headquarters in Nairobi, Kenya, today announced it has been awarded $6 million in non-dilutive grant funding from the Gates Foundation to expand access to high-quality, affordable medicines across low- and middle-income countries through its B2B procurement and integrated logistics platform.

The grant builds on the Foundation's prior $5 million support and reflects continued conviction in Axmed's execution and operating model. With additional backing from Founderful Ventures, the company has now raised a total of $13 million in capital to date.

The new funding will accelerate Axmed's expansion across Africa and support procurement programs spanning multiple therapeutic areas, including family planning and malaria products serving mothers, children, and underserved patient populations across LMICs over the next 12 to 18 months.

Since launch, Axmed has developed a geo-agnostic pooled procurement and logistics platform purpose-built for fragmented and supply-constrained healthcare markets. In 2025 alone, the platform delivered more than 1,800 metric tonnes of healthcare products and reached over 4.2 million patients, up from approximately 750,000 in 2024. Over the same period, Axmed recorded 12x year-on-year revenue growth and maintained an average 70 percent repeat purchase rate, demonstrating strong adoption and sustained buyer trust.

Through demand aggregation, price transparency, and coordinated international logistics, the platform consistently generates 30 to 35 percent cost savings for customers. These efficiencies directly expand patient reach, improve medicine availability, and shorten delivery timelines across complex operating environments.

"Although Axmed is a young organization, their model of leveraging a technology-enabled marketplace to improve access to essential medicines in emerging markets is both innovative and essential," said Denise Tuiime Mutambi, Director of Planning and Procurement at Joint Medical Stores. "They have demonstrated an exceptional ability to navigate global healthcare supply chain complexity and translate strategy into measurable and sustainable impact.

Axmed plans to operate in more than 20 countries by the end of 2026, with a target of reaching 50 million patients within three years and over 100 million within five years, positioning the platform as a core infrastructure layer for medicines procurement in underserved markets.

"This funding allows us to scale what already works while we bring in aligned long-term capital," said Emmanuel Akpakwu, Founder and CEO of Axmed. "With the continued support of the Gates Foundation, our focus is disciplined execution at scale: strengthening procurement systems, improving affordability, and ensuring high-quality medicines reliably reach the people who depend on them."

About Axmed

Axmed is a technology-enabled B2B marketplace and logistics platform that connects buyers, manufacturers, and distributors to streamline procurement and delivery of essential medicines across low- and middle-income countries. By combining pooled demand, data-driven sourcing, and integrated international logistics, Axmed reduces costs, increases supply reliability, and expands patient access to quality-assured healthcare products. Learn more at www.axmed.com.

Media Enquiries

Nanayaa Appenteng, Director, Strategic Communications & External Affairs

nanayaa.appenteng@axmed.com

Photo - https://mma.prnewswire.com/media/2905108/Axmed_Logistics.jpg

Photo - https://mma.prnewswire.com/media/2905109/Axmed.jpg

View original content to download multimedia:https://www.prnewswire.com/news-releases/axmed-secures-6m-grant-funding-to-scale-the-global-infrastructure-for-access-to-healthcare-products-302689432.html

SOURCE Axmed

 

(END) Dow Jones Newswires

February 17, 2026 08:06 ET (13:06 GMT)

應版權方要求,你需要登入查看該內容

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10